As of close of business last night, Seres Therapeutics Inc’s stock clocked out at $1.06, down -7.02% from its previous closing price of $1.14. In other words, the price has decreased by -$0.0800 from its previous closing price. On the day, 6691650 shares were traded.
Ratios:
To gain a deeper understanding of MCRB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.47 and its Current Ratio is at 2.71.
On April 21, 2023, JP Morgan started tracking the stock assigning a Neutral rating and target price of $7.
Goldman Downgraded its Neutral to Sell on July 23, 2021, whereas the target price for the stock was revised from $24 to $7.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 16 when Shaff Eric D. sold 11,549 shares for $1.08 per share. The transaction valued at 12,473 led to the insider holds 135,321 shares of the business.
Ege David S. sold 5,010 shares of MCRB for $5,411 on Feb 16. The insider now owns 73,856 shares after completing the transaction at $1.08 per share. On Feb 16, another insider, von Moltke Lisa, who serves as the insider of the company, sold 4,400 shares for $1.08 each. As a result, the insider received 4,752 and left with 16,988 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MCRB now has a Market Capitalization of 154.29M and an Enterprise Value of 240.26M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.08. Its current Enterprise Value per Revenue stands at 1.89 whereas that against EBITDA is -1.94.
Stock Price History:
Over the past 52 weeks, MCRB has reached a high of $6.87, while it has fallen to a 52-week low of $0.91. The 50-Day Moving Average of the stock is 1.1947, while the 200-Day Moving Average is calculated to be 2.6719.
Shares Statistics:
It appears that MCRB traded 4.68M shares on average per day over the past three months and 3.82M shares per day over the past ten days. A total of 125.22M shares are outstanding, with a floating share count of 97.76M. Insiders hold about 24.37% of the company’s shares, while institutions hold 51.67% stake in the company. Shares short for MCRB as of Feb 15, 2024 were 15.59M with a Short Ratio of 3.33, compared to 17.55M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 12.06% and a Short% of Float of 22.69%.
Earnings Estimates
As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.5 for the current quarter, with a high estimate of -$0.33 and a low estimate of -$1, while EPS last year was -$0.54. The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.18 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$0.9 and -$1.07 for the fiscal current year, implying an average EPS of -$0.99. EPS for the following year is -$1.38, with 7 analysts recommending between -$0.9 and -$2.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for MCRB’s current fiscal year. The highest revenue estimate was $127.8M, while the lowest revenue estimate was $123.08M, resulting in an average revenue estimate of $126.07M. In the same quarter a year ago, actual revenue was $7.13M, up 1,668.70% from the average estimate.
